Evidence map›Paper›PMID 36792189›Full record

ArticleInternal medicine (Tokyo, Japan)2023

COVID-19 Cluster in the Hematology/Respirology Ward of a University Hospital during the Seventh Wave of the SARS-CoV-2 Pandemic in Japan: A Descriptive Study.

Fumiya Ogasawara, Shohei Yoshida, Mayuka Yamane, Kazufumi Takamatsu, Yu Arakawa, Yoshie Nishida, Megumi Komatsu, Akihito Yokoyama, Yuka Yamagishi, Kensuke Kojima

Open access · diamondAbstract read
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Fumiya OgasawaraDepartment of Hematology, Kochi Medical School, Kochi University, Japan.
Shohei YoshidaDepartment of Hematology, Kochi Medical School, Kochi University, Japan.
Mayuka YamaneDepartment of Respiratory Medicine and Allergology, Kochi Medical School, Kochi University, Japan.
Kazufumi TakamatsuDepartment of Respiratory Medicine and Allergology, Kochi Medical School, Kochi University, Japan.
Yu ArakawaDepartment of Clinical Infectious Diseases, Kochi Medical School, Kochi University, Japan.
Yoshie NishidaClinical Laboratory Department, Kochi Medical School Hospital, Japan.
Megumi KomatsuNursing Department, Kochi Medical School Hospital, Japan.
Akihito YokoyamaDepartment of Respiratory Medicine and Allergology, Kochi Medical School, Kochi University, Japan.
Yuka YamagishiDepartment of Clinical Infectious Diseases, Kochi Medical School, Kochi University, Japan.
Kensuke KojimaDepartment of Hematology, Kochi Medical School, Kochi University, Japan.
Kōchi University · JPKochi Medical School Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective Patients with hematological malignancies and solid organ tumors reportedly tend to have a more severe coronavirus disease 2019 (COVID-19) trajectory than do those with other diseases. We studied the clinical features and outcomes of nosocomial severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during the seventh wave of the pandemic. Methods This study retrospectively described the characteristics of COVID-19 clusters involving patients in the hematology/respirology ward of Kochi Medical School Hospital during the seventh wave of the pandemic of SARS-CoV-2. Patients A total of 40 individuals, including 25 patients and 15 healthcare workers, were studied. The diagnosis of SARS-CoV-2 infection was based on reverse transcription polymerase chain reaction performed on nasopharyngeal samples. Results Eleven patients had hematological diseases, and 14 had respiratory diseases. Most patients presented with a fever (n=19) and/or sore throat (n=10). Lower respiratory tract symptoms and pneumonia were rather infrequent, occurring in two patients. All patients received antivirals. The maximal severities were mild in 21 patients and moderate in 2. Two asymptomatic patients with SARS-CoV-2 infection did not develop symptoms of COVID-19. Cycle threshold values in nasopharyngeal samples were significantly lower in patients with COVID-19 than in those who were asymptomatic at the time of the diagnosis with SARS-CoV-2 infection. All SARS-CoV-2-infected inpatients recovered or did not develop symptoms of COVID-19. Conclusion COVID-19 vaccination, early or preemptive treatment with antivirals, and intrinsic changes in SARS-CoV-2 may have contributed to the more favorable outcomes in our series than in previously reported nosocomial clusters.

Indexed as

COVID-19Cross InfectionHematologyAntiviral AgentsCOVID-19 VaccinesHospitals, UniversityHumansJapanPandemicsRetrospective StudiesSARS-CoV-2Antiviral AgentsCOVID-19 VaccinesCOVID-19hematological malignanciesnosocomial clusterSARS-CoV-2ward

Identifiers

PMID36792189
PMCPMC10208769
OpenAlexW4320717727

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.